Development
D
AbCellera Biologics Inc. ABCL
$4.59 $0.092.00% NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

12/31/2023 09/30/2023 06/30/2023 03/31/2023 12/31/2022
Revenue -92.17% -91.65% -71.38% -62.98% 29.37%
Total Other Revenue -- -- -- -- --
Total Revenue -92.17% -91.65% -71.38% -62.98% 29.37%
Cost of Revenue -64.98% -60.09% -51.72% -50.48% -15.63%
Gross Profit -98.42% -105.46% -80.40% -68.32% 47.45%
SG&A Expenses 12.61% 9.19% 15.44% 22.51% 37.07%
Depreciation & Amortization 25.46% 23.87% 31.47% 38.53% 34.55%
Other Operating Expenses -- -- -- -- --
Total Operating Expenses 5.65% -6.15% 6.64% 12.98% 52.59%
Operating Income -205.47% -159.71% -139.96% -123.92% 9.98%
Income Before Tax -172.79% -144.15% -125.02% -113.82% 9.10%
Income Tax Expenses -134.29% -125.92% -96.48% -87.68% 22.67%
Earnings from Continuing Operations -192.35% -152.00% -136.89% -124.49% 3.29%
Earnings from Discontinued Operations -- -- -- -- --
Extraordinary Item & Accounting Change -- -- -- -- --
Minority Interest in Earnings -- -- -- -- --
Net Income -192.35% -152.00% -136.89% -124.49% 3.29%
EBIT -205.47% -159.71% -139.96% -123.92% 9.98%
EBITDA -187.09% -150.38% -130.09% -115.34% 11.60%
EPS Basic -190.59% -151.19% -136.29% -124.17% -0.55%
Normalized Basic EPS -171.16% -141.40% -121.18% -110.86% 8.07%
EPS Diluted -205.69% -157.46% -143.50% -129.20% 3.62%
Normalized Diluted EPS -179.01% -145.32% -125.05% -113.63% 13.53%
Average Basic Shares Outstanding 1.44% 1.45% 1.65% 2.41% 3.38%
Average Diluted Shares Outstanding -3.48% -5.16% 0.04% 0.75% 2.02%
Dividend Per Share -- -- -- -- --
Payout Ratio -- -- -- -- --